Chemotherapy

Chemotherapy

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Drs. H. Jack West, Medical Director - Thoracic Oncology Program at Swedish Cancer Institute, President and CEO of GRACE, Karen Kelly - Associate...
Cancer Journey:
Cancer Type:
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer...
Cancer Journey:
Cancer Type:
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal 1st line treatment for a patient with advanced non squamous non small cell lung cancer, high PD-L1, and no driver mutation.
Cancer Journey:
Cancer Type:
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss if there is a best systemic therapy option for a patient with advanced non-squamous NSCLC, low PD-L1 and no driver mutation.
Cancer Journey:
Cancer Type:
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal approach for a fit patient with advanced squamous NSCLC and low tumor PD-L1 expression.
Cancer Journey:
Cancer Type:

Articles

Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a...
Cancer Journey:
Cancer Type:
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).
Cancer Journey:
Cancer Type:
Drs. Leora Horn, Ben Solomon, & Jack West debate whether results from a European trial of chest radiation after chemotherapy for extensive stage small cell lung cancer should lead to a change in treatment for this setting.
Cancer Journey:
Cancer Type:
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Cancer Journey:
Cancer Type:
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
Cancer Journey:
Cancer Type:

Community Forum

Greetings all, I'm a medical doctor from Vietnam. I want to discuss to you about my patient. He is 58 years old, he is hospitalize with chronic...
Cancer Journey:
Cancer Type:
My father has been dealing with prostate cancer for a couple of years now and is about to begin treatment. Does anybody have any information or...
Cancer Journey:
Cancer Type:
Disease Learning: